Abstract | BACKGROUND: OBJECTIVE: To review the cutaneous adverse events related to EGFR inhibitors. METHODS: A retrospective chart review of all cases referred for the management of cutaneous adverse events after the initiation of EGFR inhibitor therapy between the years of 2006 and 2009 was performed. The study was approved by the institutional review board. RESULTS: CONCLUSION: The most common cutaneous adverse event in our cohort was papulopustular rash, followed by eczema and xerosis. Patients were managed with symptom target therapy, and suspension of the EGFR inhibitor was rarely required. As the use of EGFR inhibitors increases, it is important to promptly identify and treat adverse events. Further studies are necessary to develop targeted therapeutic and preventative measures.
|
Authors | Amelia M Wnorowski, Aieska de Souza, Abraham Chachoua, David E Cohen |
Journal | International journal of dermatology
(Int J Dermatol)
Vol. 51
Issue 2
Pg. 223-32
(Feb 2012)
ISSN: 1365-4632 [Electronic] England |
PMID | 22250636
(Publication Type: Journal Article)
|
Copyright | © 2012 The International Society of Dermatology. |
Chemical References |
- Antineoplastic Agents
- Quinazolines
- Erlotinib Hydrochloride
- ErbB Receptors
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects)
- Drug Eruptions
(drug therapy, etiology)
- ErbB Receptors
(antagonists & inhibitors)
- Erlotinib Hydrochloride
- Female
- Humans
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
- Pancreatic Neoplasms
(drug therapy)
- Quinazolines
(adverse effects)
- Retrospective Studies
- Treatment Outcome
|